46.96
price down icon0.70%   -0.33
after-market アフターアワーズ: 46.01 -0.95 -2.02%
loading
前日終値:
$47.29
開ける:
$46.22
24時間の取引高:
464.32K
Relative Volume:
0.54
時価総額:
$3.10B
収益:
$58.89M
当期純損益:
$-240.88M
株価収益率:
-15.15
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
-1.39%
1か月 パフォーマンス:
+50.80%
6か月 パフォーマンス:
+11.46%
1年 パフォーマンス:
+34.67%
1日の値動き範囲:
Value
$46.04
$47.33
1週間の範囲:
Value
$45.80
$50.27
52週間の値動き範囲:
Value
$19.45
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1168)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
208
Name
Twitter
Name
次回の収益日
2025-02-21
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

KYMR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
46.96 3.10B 58.89M -240.88M -239.96M -3.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.45 115.69B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
529.24 53.25B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
307.99 39.22B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
577.89 35.78B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
269.63 27.68B 3.81B -644.79M -669.77M -6.24

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
04:11 AM

Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN

04:11 AM
pulisher
Jun 13, 2025

Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat

Jun 12, 2025
pulisher
Jun 11, 2025

Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT - MSN

Jun 11, 2025
pulisher
Jun 10, 2025

Kymera jumps 16% as it prepares to release phase 1 data on inflammatory diseases asset - MSN

Jun 10, 2025
pulisher
Jun 08, 2025

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? - Benzinga

Jun 08, 2025
pulisher
Jun 07, 2025

B. Riley Research Analysts Lower Earnings Estimates for KYMR - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Top 10 NASDAQ Stocks with Strong Growth Potential by Kalkine - Kalkine Media

Jun 06, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Q2 EPS Forecast for Kymera Therapeutics Boosted by Analyst - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial - Barron's

Jun 05, 2025
pulisher
Jun 05, 2025

Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51 - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621 - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

JPMorgan Chase & Co. Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Overweight” at Morgan Stanley - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics (NASDAQ:KYMR) Upgraded by B. Riley to “Buy” Rating - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

B. Riley Securities Upgrades Kymera Therapeutics (KYMR) - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics Executives and Directors Sell Shares - TradingView

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race - insights.citeline.com

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera stock draws upgrades after trial data (KYMR:NASDAQ) - Seeking Alpha

Jun 03, 2025
pulisher
Jun 03, 2025

Morgan Stanley upgrades Kymera stock rating, raises price target By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - TradingView

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Ta - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Target Boost | KYMR Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Buy” at Bank of America - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

What 6 Analyst Ratings Have To Say About Kymera Therapeutics - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Stifel Adjusts Price Target on Kymera Therapeutics to $68 From $55, Maintains Buy Rating - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan | KYMR Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Receives Upgraded Target Price and Po - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

JPMorgan Raises Kymera Therapeutics (KYMR) Target Price Amid Positive Phase 1 Data | KYMR Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Morgan Stanley Upgrades Kymera Therapeutics to Overweight From Equalweight, Raises Price Target to $79 From $49 - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Shares Boosted by Positive KT-621 Dat - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Wells Fargo reiterates overweight rating on Kymera Therapeutics stock By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
Jun 03, 2025

Where are the Opportunities in (KYMR) - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera reports promising Phase 1 results for KT-621 By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - MSN

Jun 03, 2025
pulisher
Jun 02, 2025

These 10 Stocks Blew Past Expectations - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Kymera’s STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I - Genetic Engineering and Biotechnology News

Jun 02, 2025
pulisher
Jun 02, 2025

Kymera Therapeutics (KYMR) Gains Favor with Morgan Stanley Upgra - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Kymera Therapeutics (KYMR) Gains Favor with Morgan Stanley Upgrade | KYMR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Kymera, with new data, takes early step toward a Dupixent-like pill - BioPharma Dive

Jun 02, 2025
pulisher
Jun 02, 2025

TRUIST SECURITIES MAINTAINS BUY RATING ON KYMERA STOCK AFTER POSITIVE STUDY RESULTS - Investing.com UK

Jun 02, 2025
pulisher
Jun 02, 2025

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data (NASDAQ:KYMR) - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

Citi Increases Price Target for Kymera Therapeutics (KYMR) to $6 - GuruFocus

Jun 02, 2025

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$98.73
price up icon 1.91%
$22.82
price down icon 1.17%
$34.84
price down icon 1.22%
$19.78
price down icon 1.88%
$106.57
price up icon 1.57%
biotechnology ONC
$269.63
price down icon 2.50%
大文字化:     |  ボリューム (24 時間):